Denosumab: a novel antiresorptive drug for osteoporosis.
نویسندگان
چکیده
Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
منابع مشابه
Denosumab: mechanism of action and clinical outcomes
AIMS To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. METHODS Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. FINDINGS Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pha...
متن کاملThe relationship of denosumab pharmacology and osteonecrosis of the jaws.
Denosumab is a new bone antiresorptive agent that has received approval by the Food and Drug Administration for use in patients with osteoporosis and metastatic cancer to the bones. Like the bisphosponates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ). However, because the pharmacodynamics and pharmacokinetics of denosumab differ...
متن کامل[[Antiresorptive agents in the treatment of osteoporosis].
The aim of drug treatment of osteoporosis is the balance between activity of osteoblasts and osteoclasts with aug- mentation of mineral bone density and decrease of fracture risk. Antiresorptive agents depress osteoclasts and diminish resorption of bone. They include bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, while hormone replacement therapy and calcitonin are ...
متن کاملTargeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclasts, resulting in an antiresorptive effect with a significant increase in bone mineral density. The...
متن کاملNew Antiresorptive Therapies for Postmenopausal Osteoporosis
Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component of bone remodeling activity. Current antiresorptive agents are effective, but the effectiveness of some agents is limited by real or perceived intolerance, longterm adverse events...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cleveland Clinic journal of medicine
دوره 82 2 شماره
صفحات -
تاریخ انتشار 2015